Subject: Business Continuity Plan (BCP) and Brexit resilience – Information note
Through its quality policy, Active Pharma Supplies Ltd has committed to deliver high quality products that consistently meet or exceed our customers’ expectations. These products support the pharmaceutical and nutritional product industries all over the world.
Active Pharma Supplies Ltd has implemented a Business Continuity Plan to create counter measures for the following risk events.
Fire and explosion,
Theft and vandalism,
and Business Interruption after such events.
Active Pharma Supplies capability is based on one production site located in Leyland UK, it is continually audited to identify and evaluate potential hazards. This has allowed us to get a much deeper understanding of our business, and identify the resources needed to set up appropriate continuity responses such as building safety stocks and/or transfer production to alternative providers.
To this end:
Raw materials are fully traceable and readily available in sufficient amounts.
Significant finished product stocks are maintained in our storage locations to supply
our customers’ needs, physically segregated from production areas.
Strict warehousing rules have been implemented to ensure the highest standards of product safety and integrity during storage.
We are convinced that all the measures described above are able to match our commitment to supply our customers.
Specific comment on Brexit 2019
This BCP has been updated to accommodate the uncertainty surrounding EUGMP and the wider UK pharmaceutical industry.
Firstly, it is important to understand that Active Pharma Supplies Ltd is licensed to import, distribute and repack active pharmaceuticals ingredients from third countries. A third country is any country outside the EU. Throughout our existence we have been undertaking this role and have a QMS and a business system to facilitate this process.
In the Event of UK leaving the UK without formal reciprocal trade-agreements with EU member states, EU member states will be considered third countries. Our business system will therefore revert to dealing with EU member states as third countries and material that requires importation will be transacted in this way.
Quality risk assessment will not change, and material will be assessed based on EUGMP equivalence. Our highest risk will be to cash flow and time, as extra charges and taxes will need to be paid as material crosses borders, we have implemented a facility to allow for increased cash flow requirements. There is a potential that this may lengthen shipping times, but this will be outside of our control.